Pomalidomide
Pomalidomide is an oral cancer medicine (a thalidomide analogue) used for multiple myeloma and Kaposi sarcoma in adults.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 11 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Pomalidomide (Pomalyst) is a thalidomide-related cancer medicine used with dexamethasone for multiple myeloma that keeps returning after other treatments, and for Kaposi sarcoma; it triggers the breakdown of proteins myeloma cells need to survive and boosts immune cells, on the market since about 2012 and now available generically. It is usually manageable, though tiredness, constipation and falling blood counts are common. The boxed warning covers severe birth defects and serious blood clots, so it is dispensed only through a restricted program (PS-Pomalidomide REMS) with pregnancy safeguards, and a clot-preventing medicine is usually prescribed alongside it. Treat any fever as urgent, since it can mean dangerously low white blood cells.
Clinical pearls
- Expect blood counts checked regularly and liver tests monthly, since this drug can lower white cells and injure the liver.
- It is taken on Days 1 through 21 of each 28-day cycle, with or without food, then a week off.
- Ask before starting ciprofloxacin or fluvoxamine, which raise pomalidomide levels and may need a dose cut.
- Men must use condoms with partners who could become pregnant, even after a vasectomy, and must not donate sperm.
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾
Pomalidomide must never be taken during pregnancy. It is related to thalidomide, which causes severe, life-threatening birth defects and loss of the pregnancy. Females who can become pregnant need two negative pregnancy tests before starting and must use two forms of birth control or avoid heterosexual sex during treatment and for 4 weeks after. The drug is available only through the PS-Pomalidomide REMS program.
It can also cause serious blood clots in the legs or lungs, and heart attack and stroke in people with multiple myeloma. Blood-thinning prevention is recommended, chosen based on your risk factors. Get emergency help for chest pain, sudden shortness of breath, leg swelling, or stroke signs.
Patient information guide A plain-language walkthrough of Pomalidomide, written from its FDA label.
What Pomalidomide is used for
▾
Pomalidomide capsules treat two cancers in adults:
- Multiple myeloma: with dexamethasone, after at least two prior therapies including lenalidomide and a proteasome inhibitor, with progression on or within 60 days of the last therapy.
- AIDS-related Kaposi sarcoma: after HAART has failed.
- Kaposi sarcoma in HIV-negative adults.
Both Pomalyst and Pomalidomide capsules carry these uses. The Kaposi sarcoma approvals are accelerated approvals based on response rate.
How Pomalidomide works
▾
Pomalidomide attaches to a protein called cereblon. This marks certain proteins (Aiolos and Ikaros) for destruction, which harms cancer cells and affects the immune system.
In lab studies it also worked in lenalidomide-resistant myeloma cells and worked together with dexamethasone. It boosted T cells and natural killer cells and lowered inflammatory signals such as TNF-α and IL-6.
Pomalidomide dosage
▾
Pomalidomide is a capsule taken by mouth once a day, with or without food, on Days 1 through 21 of each 28-day cycle.
- For multiple myeloma it is taken with dexamethasone.
- For AIDS-related Kaposi sarcoma, you keep taking your HIV treatment.
- Doses may be lowered or paused for low blood counts, side effects, or kidney or liver problems.
Follow your prescriber's directions and the label.
Dosing details from the FDA-approved label
From the Pomalidomide prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Multiple myeloma (MM)
- 4 mg once daily orally with or without food on Days 1 through 21 of each 28-day cycle until disease progression, given in combination with dexamethasone
- Kaposi sarcoma (KS)
- 5 mg once daily taken orally with or without food on Days 1 through 21 of each 28-day cycle until disease progression or unacceptable toxicity
- Continue HAART as HIV treatment in patients with AIDS-related KS
- MM with strong CYP1A2 inhibitor use unavoidable
- Reduce POMALYST dose to 2 mg
- Avoid concomitant use of strong CYP1A2 inhibitors
- MM with severe renal impairment requiring dialysis
- 3 mg orally daily
- Take after completion of dialysis procedure on hemodialysis days
- KS with severe renal impairment requiring dialysis
- 4 mg orally daily
- Take after completion of dialysis procedure on hemodialysis days
- MM with mild or moderate hepatic impairment (Child-Pugh A or B)
- 3 mg orally daily
- MM with severe hepatic impairment (Child-Pugh C)
- 2 mg
- KS with mild, moderate, or severe hepatic impairment (Child-Pugh A, B, or C)
- 3 mg orally daily
Read the label’s full dosing text
2 DOSAGE AND ADMINISTRATION MM: 4 mg per day taken orally on Days 1 through 21 of repeated 28-day cycles until disease progression ( 2.2 ). Refer to section 14.1 for dexamethasone dosing ( 14.1 ). KS: 5 mg per day taken orally on Days 1 through 21 of repeated 28-day cycles until disease progression or unacceptable toxicity ( 2.3 ). Modify the dosage for certain patients with renal impairment ( 2.7 , 8.6 ) or hepatic impairment ( 2.8 , 8.7 ). 2.1 Pregnancy Testing Prior to Administration Females of reproductive potential must have negative pregnancy testing and use contraception methods before initiating pomalidomide capsules [see Warnings and Precautions ( 5.1 ) and Use in Specific Populations ( 8.1 , 8.3 )] . 2.2 Recommended Dosage for Multiple Myeloma The recommended dosage of pomalidomide capsules is 4 mg once daily orally with or without food on Days 1 through 21 of each 28-day cycle until disease progression. Give pomalidomide capsules in combination with dexamethasone [see Clinical Studies ( 14.1 )] . 2.3 Recommended Dosage for Kaposi Sarcoma The recommended dosage of pomalidomide capsules is 5 mg once daily taken orally with or without food on Days 1 through 21 of each 28-day cycle until disease progression or unacceptable toxicity. Continue HAART as HIV treatment in patients with AIDS-related Kaposi sarcoma (KS) [see Clinical Studies ( 14.2 )] . 2.4 Dosage Modifications for Hematologic Adverse Reactions Multiple Myeloma: Dosage Modifications for Hematologic Adverse Reactions Initiate a new cycle of pomalidomide capsules in patients with multiple myeloma (MM) when the neutrophil count is at least 500 per mcL and the platelet count is at least 50,000 per mcL. Dosage modification for pomalidomide capsules for hematologic adverse reactions in patients with MM are summarized in Table 1. Table 1: Dosage Modifications for Pomalidomide Capsules for Hematologic in MM Adverse Reaction Severity Dosage Modification Neutropenia [see Warnings and Precautions ( 5.5 )] ANC less than 500 per mcL or febrile neutropenia (fever greater than or equal to 38.5°C and ANC less than 1,000 per mcL) Withhold pomalidomide capsules until ANC is greater than or equal to 500 per mcL; follow CBC weekly.
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Pomalidomide side effects
▾
Common side effects include:
Common side effects
- Tiredness and weakness
- Low white blood cells (neutropenia) and low red blood cells (anemia)
- Constipation
- Nausea
- Diarrhea
- Shortness of breath
- Upper respiratory infections
- Back pain and fever
- Rash, in Kaposi sarcoma
When to get medical help
- Pregnancy or suspected pregnancy: stop the drug and call your doctor right away.
- Signs of a blood clot: leg swelling or pain, sudden shortness of breath, chest pain, or stroke symptoms. Get emergency help.
- Fever or signs of infection, which can mean dangerously low white blood cells.
- Severe rash, blistering, peeling skin, or fever with rash and swollen glands.
- Swelling of the face, lips or throat, or trouble breathing (allergic reaction).
- Yellowing of skin or eyes, or abnormal liver tests, which can signal liver injury.
- Dizziness or confusion that interferes with safe activities.
- Numbness or tingling (neuropathy).
Pomalidomide warnings and precautions
▾
- Birth defects: never use in pregnancy; strict pregnancy testing and birth control are required.
- Blood clots: deep vein clots, lung clots, heart attack and stroke; clot prevention is recommended.
- Low blood counts: neutropenia is most common; blood counts are monitored.
- Liver injury: including fatal liver failure; liver tests are monthly.
- Severe skin reactions and allergic reactions: stop the drug.
- Dizziness, confusion, neuropathy, tumor lysis syndrome, and rare leukemia reports.
Pomalidomide interactions
▾
A few interactions matter most:
- Strong CYP1A2 inhibitors (ciprofloxacin, fluvoxamine): they raise pomalidomide levels and the risk of toxicity, so avoid them or lower the dose.
- Pembrolizumab with a thalidomide analogue and dexamethasone: increased deaths in myeloma trials.
- Medicines that cause dizziness or confusion: can add to those effects.
Interactions listed in the FDA-approved label
From the Pomalidomide prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Strong CYP1A2 inhibitors (e.g. ciprofloxacin and fluvoxamine): Co-administration of fluvoxamine, a strong CYP1A2 inhibitor, increased Cmax and AUC of pomalidomide by 24% and 125% respectively in healthy subjects, and increased exposure may increase the risk of exposure related toxicities. Avoid concomitant use; if unavoidable, reduce the pomalidomide dose to 2 mg.
Read the label’s full interactions text
7 DRUG INTERACTIONS Strong CYP1A2 Inhibitors: Avoid concomitant use of strong CYP1A2 inhibitors. If concommitant use of a strong CYP1A2 inhibitor is unavoidable, reduce pomalidomide capsules dose to 2 mg ( 2.6 , 7.1 , 12.3 ). 7.1 Drugs That Affect Pomalidomide Plasma Concentrations CYP1A2 inhibitors : In healthy subjects, co-administration of fluvoxamine, a strong CYP1A2 inhibitor, increased C max and AUC of pomalidomide by 24% and 125% respectively [see Clinical Pharmacology (12.3) ] . Increased pomalidomide exposure may increase the risk of exposure related toxicities. Avoid co-administration of strong CYP1A2 inhibitors (e.g. ciprofloxacin and fluvoxamine) . If co-administration is unavoidable, reduce the pomalidomide capsules dose [see Dosage and Administration (2.6) ] .
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Pomalidomide
▾
- Not for use in pregnancy or with a prior severe allergy to pomalidomide.
- Females who can become pregnant need two negative tests and two forms of birth control.
- Males need condoms during treatment and for up to 4 weeks after, and must not donate sperm.
- No blood donation during treatment and for 4 weeks after.
- Do not breastfeed.
- Tell your doctor about clot risks, liver disease, or kidney disease; doses may be adjusted.
- Not established in children.
Pomalidomide overdose
▾
Hemodialysis can remove pomalidomide from the blood. If you take too much, get medical help right away.
What Pomalidomide does in the body
▾
At the 4 mg dose, there was no relationship between how much drug was in the body and its effectiveness or safety. In a study of 72 people, doses of 4 mg and 20 mg did not significantly prolong the QTc (a heart rhythm measure).
How your body processes Pomalidomide
▾
Peak levels occur about 2 to 3 hours after a dose. A high-fat, high-calorie meal delays the peak by about 2.5 hours and lowers peak levels somewhat. The liver breaks it down mainly using CYP1A2 and CYP3A4. Its half-life is about 7.5 hours in patients, and most of it leaves through urine and stool. Liver impairment raises drug exposure, as does kidney failure requiring dialysis.
How to store Pomalidomide
▾
Store at 20°C to 25°C (68°F to 77°F); excursions permitted from 15°C to 30°C (59°F to 86°F) .
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Supplements & herbs that interact with Pomalidomide
207 supplements and herbal products have documented interactions with Pomalidomide in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 3
- Moderate · 162
- Minor · 42
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Pomalidomide: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Pomalidomide — the kind of thing our pharmacy team would talk through with you at the counter.
What is pomalidomide used for?
▾
How do I take it?
▾
Is it safe if I could become pregnant, or if my partner could?
▾
What side effects should I expect?
▾
When should I call my doctor right away?
▾
Are there medicines I should avoid?
▾
Is Pomalidomide available over the counter?
▾
When was Pomalidomide first available?
▾
Who makes Pomalidomide?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Pomalidomide on HelloPharmacist
Pomalidomide forms and strengths (how it comes)
Pomalidomide is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Capsule
How this form is used
- Pomalyst and Pomalidomide capsules are used with dexamethasone for adults with multiple myeloma after at least two prior therapies.
- Pomalyst and Pomalidomide capsules are used for adults with AIDS-related Kaposi sarcoma after HAART failure, or HIV-negative Kaposi sarcoma.
- Pomalyst and Pomalidomide capsules are taken by mouth once daily, with or without food, on Days 1 through 21 of each 28-day cycle.
- Pomalyst and Pomalidomide capsules are available only through the PS-Pomalidomide REMS program.
Pomalidomide on the U.S. market: products, makers and brands
How Pomalidomide appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
12 companies list 47 Pomalidomide product records with the FDA, mostly as capsule; the earliest marketing or approval year on record is 2012. Brand names on the directory include Pomalyst; the rest are generics.
Also listed with the FDA, not a patient dose form: Powder (11) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How widely Pomalidomide is used (Medicaid data)
A general measure of how commonly Pomalidomide is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Pomalidomide is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Pomalidomide prescribed? Of the 1,601 medications we measure, Pomalidomide ranks #1,175 by Medicaid prescriptions — more than 27% of them.
Utilization by Pomalidomide product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
pomalidomide 4 MG Oral Capsule Most dispensed
Summed across the 2 of 14 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1369734
pomalidomide 2 MG Oral Capsule
Summed across the 2 of 14 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1369726
pomalidomide 3 MG Oral Capsule
Summed across the 1 of 14 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1369730
pomalidomide 1 MG Oral Capsule
Summed across the 1 of 13 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1369718
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Pomalidomide, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 6 of 55 listed Pomalidomide NDCs with Medicaid activity.
Compare Pomalidomide products
A representative set of FDA-listed product records for Pomalidomide — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Capsule | ||||
| 1 mg | Oral | Apotex Corp. | ANDA | View NDC → |
| 2 mg | Oral | Apotex Corp. | ANDA | View NDC → |
| 3 mg | Oral | Apotex Corp. | ANDA | View NDC → |
| 4 mg | Oral | Apotex Corp. | ANDA | View NDC → |
| 1 mg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| 2 mg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| 3 mg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| 4 mg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| 1 mg | Oral | Breckenridge Pharmaceutical, Inc. | ANDA | View NDC → |
| 2 mg | Oral | Breckenridge Pharmaceutical, Inc. | ANDA | View NDC → |
| 3 mg | Oral | Breckenridge Pharmaceutical, Inc. | ANDA | View NDC → |
| 4 mg | Oral | Breckenridge Pharmaceutical, Inc. | ANDA | View NDC → |
| 1 mg | Oral | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| 2 mg | Oral | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| 3 mg | Oral | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| 4 mg | Oral | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| 1 mg | Oral | Celgene Corporation | NDA | View NDC → |
| 2 mg | Oral | Celgene Corporation | NDA | View NDC → |
| 3 mg | Oral | Celgene Corporation | NDA | View NDC → |
| 4 mg | Oral | Celgene Corporation | NDA | View NDC → |
| 1 mg | Oral | Cipla USA Inc. | ANDA | View NDC → |
| 2 mg | Oral | Cipla USA Inc. | ANDA | View NDC → |
| 3 mg | Oral | Cipla USA Inc. | ANDA | View NDC → |
| 4 mg | Oral | Cipla USA Inc. | ANDA | View NDC → |
| 1 mg | Oral | Dr. Reddy's Laboratories Inc. | ANDA | View NDC → |
| 2 mg | Oral | Dr. Reddy's Laboratories Inc. | ANDA | View NDC → |
| 3 mg | Oral | Dr. Reddy's Laboratories Inc. | ANDA | View NDC → |
| 4 mg | Oral | Dr. Reddy's Laboratories Inc. | ANDA | View NDC → |
| 1 mg | Oral | Natco Pharma Limited | ANDA | View NDC → |
| 2 mg | Oral | Natco Pharma Limited | ANDA | View NDC → |
| 3 mg | Oral | Natco Pharma Limited | ANDA | View NDC → |
| 4 mg | Oral | Natco Pharma Limited | ANDA | View NDC → |
| 2 mg | Oral | Novadoz Pharmaceuticals LLC | ANDA | View NDC → |
| 3 mg | Oral | Novadoz Pharmaceuticals LLC | ANDA | View NDC → |
| 4 mg | Oral | Novadoz Pharmaceuticals LLC | ANDA | View NDC → |
| 1 mg | Oral | Sandoz Inc | ANDA | View NDC → |
| 2 mg | Oral | Sandoz Inc | ANDA | View NDC → |
| 3 mg | Oral | Sandoz Inc | ANDA | View NDC → |
| 4 mg | Oral | Sandoz Inc | ANDA | View NDC → |
| 1 mg | Oral | Sun Pharmaceutical Industries, Inc. | ANDA | View NDC → |
| 2 mg | Oral | Sun Pharmaceutical Industries, Inc. | ANDA | View NDC → |
| 3 mg | Oral | Sun Pharmaceutical Industries, Inc. | ANDA | View NDC → |
| 4 mg | Oral | Sun Pharmaceutical Industries, Inc. | ANDA | View NDC → |
| 1 mg | Oral | Teva Pharmaceuticals, Inc. | ANDA | View NDC → |
| 2 mg | Oral | Teva Pharmaceuticals, Inc. | ANDA | View NDC → |
| 3 mg | Oral | Teva Pharmaceuticals, Inc. | ANDA | View NDC → |
| 4 mg | Oral | Teva Pharmaceuticals, Inc. | ANDA | View NDC → |
Showing 47 of 47 products — FDA National Drug Code Directory. See every product, package size and price: browse all 47 Pomalidomide NDCs →
Pomalidomide side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Pomalidomide — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Pomalidomide in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Pomalidomide FDA approval history
How Pomalidomide went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Pomalidomide recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Pomalidomide recalls since July 2021.
✅No Pomalidomide recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 1369713 1 dose form · 4 strengths
-
Dose form (SCDF) Oral Capsule RxCUI 1369717In current FDA listings
Look up RxCUI 1369713 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Pomalidomide supply and shortage status
Whether Pomalidomide is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
Pomalidomide brand names
Pomalidomide is sold under one brand name in the FDA directory — Pomalyst. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Pomalidomide: manufacturers and labelers
12 companies list Pomalidomide products with the FDA. By number of product records, the largest are Apotex Corp., Aurobindo Pharma Limited, Breckenridge Pharmaceutical, Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Pomalidomide drug class (RxNorm)
Pomalidomide belongs to the Thalidomide Analog class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Pomalidomide page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Celgene Corporation is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →